IMRX Company Profile and Key Details

IMRX has shown mixed momentum, gaining 13.27% over the past week and -14.34% over the past quarter, though year-to-date performance is down -27.36%. Short-term trend indicators are mixed aligned (SMA20 5.83%, SMA50 -2.86%, SMA200 4.5%). The stock’s 14-day RSI is 52.55 (neutral), while the ATR of 0.34 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.02% below its high and over 376.36% above its low. Average 10-day trading volume of 582.89 thousand shares is below the 3-month average of 1.65 million, indicating normal recent market interest.

Immuneering Corporation has 36.32 million shares outstanding. The public float is 27.54 million shares, elevated short interest at 5.66% of float. This equals 1.56 million shares. The short ratio is 2.09 days. Institutional investors hold 11.71% of the float. Insiders own 21.08%. Cormorant Asset Management, LP holds 2.90 million shares, Zeskind Benjamin J. has 2.31 million shares and CARPENTER ROBERT J has 1.15 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Immuneering Corporation generated EPS of -$1.78 over the past year. Five-year average earnings growth is -46.45%. Wall Street analysts project EPS growth of 7.24% annually over the next five years. The latest quarter delivered EPS of -$377.23. The next quarter is forecast at -$0.31. Next year's EPS is expected at -$7.16. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $8.00. The high target offers 472.52% upside. The low target suggests 52.67% downside. The mean target is $14.07. This offers 168.51% upside. Immuneering Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 101854.91%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 93001.44% in August 08, 2024.

Immuneering Corporation (NASDAQ:IMRX) closed at $5.24 USD, gaining $0.14 (2.75%) from the previous close of $5.10. The stock is currently mid-range between its 52-week high and low $1.10 and $10.08. With a market capitalization of about $190.22 million, Immuneering Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 1.72 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Immuneering Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Benjamin J. Zeskind, the company employs approximately 54 people and listed since July 30, 2021. Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.

Immuneering Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.07. This means the shares are trading above this model’s fair value.

Immuneering Corporation (NASDAQ:IMRX) shares are down -27.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Immuneering Corporation trading at a premium to the broader market with a P/E of -3.33. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.43, suggesting 213.55% upside. Our AI forecast model points to short-term weakness (-1.34% over two weeks), a medium-term fall (-7.63% over three months), and a longer-term gain (8.4% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Immuneering Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.34%, with price expected at $5.17 by March 11, 2026, within a range of $4.34 to $6.02 3-Month Outlook: Projected fall of -7.63%, reaching $4.84 by May 25, 2026, with a range of $4.67 to $5.00. 1-Year Outlook: Projected gain of 8.4%, with price at $5.68 by February 25, 2027, within a range of $5.41 to $6.02.

Immuneering Corporation trades at a P/E ratio of -3.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.91 suggesting the stock is closer to book value. The P/FCF stands at -3.8, also above market averages.